Thrombocytopenia is common occurrence among severe and critical COVID-19 patients, and mechanistic studies further suggested that direct activation of platelets by the SARS-CoV-2 virus, along with the potentiation of their prothrombotic function and inflammatory response via Spike/ACE2 interactions [54]. This evidence concerns the gene ACE2 and COVID-19.